Objective To observe the clinical value of ^99mTc-3PRGD₂ molecular image in evaluating the effect of recombinant endostatin.

Methods We enrolled 72 NSCLC patients, among which 36 patients in endostar plus chemotherapy group (observation group) and 36 patients in chemotherapy alone group (control group). Kaplan-Meier survival analysis curves were used to analyze the difference of progression-free survival(PFS) between two groups. The correlation of PFS with ^99mTc-3PRGD₂ SPECT/CT imaging T/N value difference before treatment and after four cycles of treatment with PFS was calculated by linear correlation.

Results The T/N value in control group before and after treatment were (6.89±2.03) and (6.76±2.01) (P=0.073), while those in observation group were (6.74±2.22) and (3.84±1.14) (P < 0.001). The difference of T/N value before and after treatment was significantly different between observation group and control group ((2.906±1.86) vs. (0.131±0.42), P < 0.001) and the change of T/N value in observation group was closely related to PFS (r=0.879, P < 0.001). Kaplan-Meier survival analysis by Log rank test showed mPFS in observation group and control group were (7.417±0.42) months and (6.194±0.26) months (P=0.003).

Conclusion The ^99mTc-3PRGD₂ molecular imaging T/N value significantly changes before and after treatment in observation group and the change of T/N value is closely related to PFS, which suggest ^99mTc-3PRGD₂ molecular imaging has clinical value in the assessment of recombinant endostatin efficacy in future.